Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$7.48 -0.3%	$6.61	$4.25 ▼ $9.85	$2.77B	0.41	4.52 million shs	1.88 million shs
KYMR Kymera Therapeutics	$44.10 +3.5%	$44.17	$19.44 ▼ $53.27	$3.15B	2.18	660,761 shs	508,269 shs
PHAR Pharming Group	$13.70 +8.2%	$10.98	$6.73 ▼ $17.08	$938.65M	0.02	12,730 shs	19,253 shs
SRRK Scholar Rock	$35.49 +2.6%	$35.71	$6.76 ▼ $46.98	$3.41B	0.48	1.85 million shs	2.05 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	-10.30%	+10.42%	+67.92%	+28.43%
KYMR Kymera Therapeutics	0.00%	+3.45%	-3.82%	+49.54%	-9.17%
PHAR Pharming Group	0.00%	+17.60%	+36.32%	+31.41%	+67.48%
SRRK Scholar Rock	0.00%	+12.99%	-9.26%	+18.30%	+283.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.18 of 5 stars	2.0	4.0	4.0	2.8	3.3	1.3
KYMR Kymera Therapeutics	2.7175 of 5 stars	4.6	1.0	0.0	1.5	2.5	0.0
PHAR Pharming Group	2.3687 of 5 stars	3.5	3.0	0.0	2.8	0.0	0.6
SRRK Scholar Rock	4.5817 of 5 stars	4.6	0.0	4.4	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.00	Hold	$9.00	20.30% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	34.04% Upside
PHAR Pharming Group	3.00	Buy	$30.00	118.98% Upside
SRRK Scholar Rock	3.20	Buy	$45.75	28.91% Upside

Current Analyst Ratings Breakdown

Latest PHAR, BHC, KYMR, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.29	$7.71 per share	0.97	$0.40 per share	18.70
KYMR Kymera Therapeutics	$47.07M	66.99	N/A	N/A	$13.59 per share	3.25
PHAR Pharming Group	$297.20M	3.16	$0.07 per share	184.81	$3.50 per share	3.91
SRRK Scholar Rock	$33.19M	102.79	N/A	N/A	$2.43 per share	14.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	$0.26	28.77	1.61	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	456.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	11/11/2025 (Estimated)

Latest PHAR, BHC, KYMR, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	141.90	1.31	0.98
KYMR Kymera Therapeutics	N/A	8.32	8.32
PHAR Pharming Group	0.38	2.79	2.07
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
KYMR Kymera Therapeutics	N/A
PHAR Pharming Group	0.03%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.05%
KYMR Kymera Therapeutics	16.01%
PHAR Pharming Group	2.07%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.33 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

PHAR, BHC, KYMR, and SRRK Headlines

Recent News About These Companies

Nuveen LLC Takes Position in Scholar Rock Holding Corporation $SRRK

August 24 at 3:41 AM | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Research Coverage Started at Jefferies Financial Group

August 24 at 2:45 AM | americanbankingnews.com

Candriam S.C.A. Trims Stock Position in Scholar Rock Holding Corporation $SRRK

August 23 at 7:07 AM | marketbeat.com

Aberdeen Group plc Sells 50,705 Shares of Scholar Rock Holding Corporation $SRRK

August 23 at 4:42 AM | marketbeat.com

Russell Investments Group Ltd. Purchases 182,859 Shares of Scholar Rock Holding Corporation $SRRK

August 23 at 4:26 AM | marketbeat.com

Scholar Rock Holding Corporation $SRRK Shares Acquired by Swiss National Bank

August 23 at 3:56 AM | marketbeat.com

Scholar Rock Holding Corporation $SRRK Stake Lifted by Vanguard Group Inc.

August 23 at 3:35 AM | marketbeat.com

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

August 21 at 12:52 PM | insidermonkey.com

Scholar Rock assumed with a Buy at Jefferies

August 21 at 9:02 AM | msn.com

A Closer Look at Scholar Rock (SRRK) Valuation Following Landmark Phase 3 Data and FDA Priority Review

August 21 at 9:02 AM | finance.yahoo.com

Lord Abbett & CO. LLC Boosts Holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 17, 2025 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | businesswire.com

Scholar Rock publishes SAPPHIRE trial data in The Lancet

August 15, 2025 | msn.com

Scholar Rock Holding: Upcoming Milestone Approaches

August 13, 2025 | seekingalpha.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by Informed Momentum Co LLC

August 13, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $45.14 Average PT from Brokerages

August 13, 2025 | americanbankingnews.com

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12, 2025 | msn.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11, 2025 | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, BHC, KYMR, and SRRK Company Descriptions

Bausch Health Cos NYSE:BHC

$7.48 -0.02 (-0.25%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.66 +0.18 (+2.39%)

As of 08/22/2025 07:48 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Kymera Therapeutics NASDAQ:KYMR

$44.10 +1.51 (+3.55%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$43.54 -0.56 (-1.26%)

As of 08/22/2025 07:51 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Pharming Group NASDAQ:PHAR

$13.70 +1.04 (+8.21%)

Closing price 08/22/2025 03:52 PM Eastern

Extended Trading

$13.27 -0.43 (-3.14%)

As of 08/22/2025 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Scholar Rock NASDAQ:SRRK

$35.49 +0.90 (+2.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$35.70 +0.20 (+0.58%)

As of 08/22/2025 06:56 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time